Open AccessInfluence of value of minimal residual disease at risk of developing recurrence of relapse in patients with acute lymphoblastic leukemia
Author(s) -
Е. А. Столярова,
Н. В. Мигаль,
Mikhail Belevtsev,
Liudmila Movchan,
О. И. Быданов,
Alexander Popov,
Larisa Fechina,
О. В. Алейникова
Publication year - 2019
Publication title -
vescì nacyânalʹnaj akadèmìì navuk belarusì. seryâ medycynskìh navuk
Language(s) - English
Resource type - Journals
eISSN - 2524-2350
pISSN - 1814-6023
DOI - 10.29235/1814-6023-2019-16-2-202-215
Subject(s) - minimal residual disease , lymphoblastic leukemia , medicine , risk stratification , oncology , induction therapy , disease , residual , complete remission , leukemia , chemotherapy , algorithm , computer science
Minimal residual disease (MRD) is the most significant predictor of the relapse in patients with acute lymphoblastic leukemia (ALL). MRD evaluation is necessary not only for the prediction of the relapse, but for additional stratification of patients by the risk groups in order to address the issue of the therapy individualization and to evaluate the therapy quality. This study analyzes the MRD parameters in patients with ALL at the stage of induction therapy and evaluates the eect of the value of the minimum residual disease on survival rates and the risk of relapse in patients with ALL treated according to protocol ALL-MB 2008.